Bicycle Therapeutics (BCYC) Upgraded by Zacks Investment Research to Buy

0
45

Bicycle Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Bicycle Therapeutics Upgraded by Zacks Investment Research on 10-11-21. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

Shares of Bicycle Therapeutics traded up $0.98 on Monday, reaching $53.73. 686935 shares of the stock traded hands, compared to its average volume of 368671. Shares of Bicycle Therapeutics were trading at $53.73 on Monday. The firm’s 50 day moving average is $37.52 and its 200 day moving average is $30.70.Bicycle Therapeutics has a 12 month low of $52.75 and a 12 month high of $55.90. While on yearly highs and lows, Bicycle Therapeutics’s today has traded high as $55.90 and has touched $52.75 on the downward trend. See More Analyst Rating at: RATING

Bicycle Therapeutics Earnings and What to expect: 

Bicycle Therapeutics last announced its quarterly earnings data on August 5th, 2021. The reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by $0.03. The business earned $1.79 million during the quarter, compared to analysts’ expectations of $2.51 million. Bicycle Therapeutics has generated ($2.66) earnings per share over the last year (($2.82) diluted earnings per share). Earnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($2.82) to ($3.01) per share. Bicycle Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($2.82) to ($3.01) per share. The P/E ratio of Bicycle Therapeutics is -19.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Bicycle Therapeutics is -19.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Bicycle Therapeutics has a P/B Ratio of 9.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Bicycle Therapeutics (BCYC) Moving Average Technical Analysis

5 day Moving Average is $48.36 And 5 day price change is $9.63 (21.84%)  with average volume for 5 day average is 1,057,560. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $44.04 and 20 day price change is $14.23 (36.03%) and average 20 day moving volume is 448,090. 50 day moving average is $37.52  and 50 day price change is $22.13 ( 70.03%)  and with average volume for 50 days is : 279,562. 200 day moving average is $30.70  and 200 day price change is $33.98 (172.05%)  and with average volume for 200 days is : 174,600.

Other owners latest trading in Bicycle Therapeutics :

  • On 10/5/2021 shares held by Woodstock Corp were 10,682 which equates to market value of $0.44M and appx 0.10% owners of Bicycle Therapeutics
  • On 8/25/2021 shares held by Marshall Wace LLP were 7,694 which equates to market value of $0.23M and appx 0.00% owners of Bicycle Therapeutics
  • On 8/23/2021 shares held by Morgan Stanley were 66,206 which equates to market value of $2.01M and appx 0.00% owners of Bicycle Therapeutics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 48.67% for Bicycle Therapeutics

See More Analyst Rating at: RATING